D-Serine in Neuropsychiatric Disorders: New Advances (Q59052088)

https://api.crossref.org/works/10.1155%2F2014%2F859735

The presence of free D-serine in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-Serine Production, Degradation, and Transport in ALS: Critical Role of Methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Distribution of free D-serine in vertebrate brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Activity-dependent synaptic plasticity of NMDA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptor subunits: function and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glycine potentiates the NMDA response in cultured mouse brain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Free D-aspartate and D-serine in the mammalian brain and periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Metabolism of the neuromodulator D-serine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine signalling in the brain: friend and foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptor regulation by D-serine: new findings and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Brain D-amino acids: a novel class of neuromodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A critical role for the glial-derived neuromodulator D-serine in the age-related deficits of cellular mechanisms of learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glia-derived D-serine controls NMDA receptor activity and synaptic memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

d -serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Excitatory amino acids as a final common pathway for neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

21 January 2018

Excitotoxic cell death

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptor pathways as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

The Yin and Yang of NMDA receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptor regulation of cell death in the rat olfactory bulb

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Serine racemase and the serine shuttle between neurons and astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Immunohistochemical evidences for localization and production of D-serine in some neurons in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Changes in D-serine levels and localization during postnatal development of the rat vestibular nuclei

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neuronal D-serine regulates dendritic architecture in the somatosensory cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Serine racemase is predominantly localized in neurons in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine regulation of NMDA receptor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Long-term potentiation depends on release of D-serine from astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Activation of NR2B-containing NMDA receptors is not required for NMDA receptor-dependent long-term depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Activation of NR2A-containing NMDA receptors is not obligatory for NMDA receptor-dependent long-term potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate released from glial cells synchronizes neuronal activity in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ß production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

High dose D-serine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Oxidative stress, glutamate, and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Plasma levels of D-serine in Brazilian individuals with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Renal tubular necrosis induced by compounds structurally related to d-serine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Disposition of D-serine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate receptors as therapeutic targets for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Apathy: a neuropsychiatric syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NR2B selective NMDA receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Ketamine for treatment-resistant depression: ready or not for clinical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Acute D-serine treatment produces antidepressant-like effects in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naïve patient with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Stress-restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Gonadal and adrenal steroids regulate neurochemical and structural plasticity of the hippocampus via cellular mechanisms involving NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neurocognitive functioning in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Effects of D-cycloserine on extinction: translation from preclinical to clinical work

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Is D-cycloserine a prodrug for D-serine in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Fibrillar Abeta (1-42) enhances NMDA receptor sensitivity via the integrin signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

The glutamatergic system and Alzheimer's disease: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

N-cadherin regulates p38 MAPK signaling via association with JNK-associated leucine zipper protein: implications for neurodegeneration in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Neuronal death enhanced by N-methyl-D-aspartate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Regulation of NMDA receptor trafficking by amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Possible role of D-serine in the pathophysiology of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Glutamic acid concentration in brains of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Small G Protein Signaling in Neuronal Plasticity and Memory Formation: The Specific Role of Ras Family Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

NMDA receptors in clinical neurology: excitatory times ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

New targets for pharmacological intervention in the glutamatergic synapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A preliminary study of D-cycloserine treatment in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Effects of low-dose D-serine on recognition and working memory in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

The role of D-amino acids in amyotrophic lateral sclerosis pathogenesis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-amino acid oxidase controls motoneuron degeneration through D-serine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

D-Amino acid oxidase: structure, catalytic mechanism, and practical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Role of renal D-amino-acid oxidase in pharmacokinetics of D-leucine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Synthesis and biological evaluation of D-amino acid oxidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Why is D-serine nephrotoxic and alpha-aminoisobutyric acid protective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Spinal D-amino acid oxidase contributes to neuropathic pain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

A series of D-amino acid oxidase inhibitors specifically prevents and reverses formalin-induced tonic pain in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Up-regulation of neurotrophic factors by cinnamon and its metabolite sodium benzoate: therapeutic implications for neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F859735